Citation
Zhang, Peng, et al. "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19." Circulation Research, vol. 126, no. 12, 2020, pp. 1671-1681.
Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020;126(12):1671-1681.
Zhang, P., Zhu, L., Cai, J., Lei, F., Qin, J. J., Xie, J., Liu, Y. M., Zhao, Y. C., Huang, X., Lin, L., Xia, M., Chen, M. M., Cheng, X., Zhang, X., Guo, D., Peng, Y., Ji, Y. X., Chen, J., She, Z. G., ... Li, H. (2020). Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research, 126(12), 1671-1681. https://doi.org/10.1161/CIRCRESAHA.120.317134
Zhang P, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020 06 5;126(12):1671-1681. PubMed PMID: 32302265.
TY - JOUR
T1 - Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
AU - Zhang,Peng,
AU - Zhu,Lihua,
AU - Cai,Jingjing,
AU - Lei,Fang,
AU - Qin,Juan-Juan,
AU - Xie,Jing,
AU - Liu,Ye-Mao,
AU - Zhao,Yan-Ci,
AU - Huang,Xuewei,
AU - Lin,Lijin,
AU - Xia,Meng,
AU - Chen,Ming-Ming,
AU - Cheng,Xu,
AU - Zhang,Xiao,
AU - Guo,Deliang,
AU - Peng,Yuanyuan,
AU - Ji,Yan-Xiao,
AU - Chen,Jing,
AU - She,Zhi-Gang,
AU - Wang,Yibin,
AU - Xu,Qingbo,
AU - Tan,Renfu,
AU - Wang,Haitao,
AU - Lin,Jun,
AU - Luo,Pengcheng,
AU - Fu,Shouzhi,
AU - Cai,Hongbin,
AU - Ye,Ping,
AU - Xiao,Bing,
AU - Mao,Weiming,
AU - Liu,Liming,
AU - Yan,Youqin,
AU - Liu,Mingyu,
AU - Chen,Manhua,
AU - Zhang,Xiao-Jing,
AU - Wang,Xinghuan,
AU - Touyz,Rhian M,
AU - Xia,Jiahong,
AU - Zhang,Bing-Hong,
AU - Huang,Xiaodong,
AU - Yuan,Yufeng,
AU - Loomba,Rohit,
AU - Liu,Peter P,
AU - Li,Hongliang,
Y1 - 2020/04/17/
PY - 2020/4/18/pubmed
PY - 2020/6/19/medline
PY - 2020/4/18/entrez
KW - COVID-19
KW - angiotensin II receptor blocker
KW - angiotensin-converting enzyme inhibitor
KW - coronavirus
KW - hypertension
KW - inpatients
SP - 1671
EP - 1681
JF - Circulation research
JO - Circ Res
VL - 126
IS - 12
N2 - RATIONALE: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension. OBJECTIVE: To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19. METHODS AND RESULTS: This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57-69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19-0.92]; P=0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted hazard ratio, 0.37 [95% CI, 0.15-0.89]; P=0.03). Further subgroup propensity score-matched analysis indicated that, compared with use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted hazard ratio, 0.30 [95% CI, 0.12-0.70]; P=0.01) in patients with COVID-19 and coexisting hypertension. CONCLUSIONS: Among hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.
SN - 1524-4571
UR - https://www.unboundmedicine.com/medline/citation/32302265/full_citation
L2 - https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.317134?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed
DB - PRIME
DP - Unbound Medicine
ER -